ESTRELLA IMMUNOPHARMA, INC.
(ESLA)Financial Statements · SEC EDGAR XBRL
Net Income
-$13.1M
-78.7%
EPS
$-0.35
-29.6%
Op. Income
-$13.1M
-78.7%
Source: SEC EDGAR XBRL
Breakdown
Revenues
Operating Expenses & Income
Research & Development
Total Operating Expenses
Operating Income
Non-Operating Income/Expense
Pre-Tax Income
Income Tax Expense
Net Income
EPS (Basic)
EPS (Diluted)
Shares Outstanding (Diluted)